Mainz Biomed (NASDAQ: MYNZ) has announced that its non-invasive colorectal cancer (CRC) screening test—ColoAlert—has been registered and approved for distribution by the Swiss regulatory and supervisory authority, Swissmedic.
According to Mainz, despite there being more than 13 CRC screening programs in Switzerland, participation rates fall below 50%. The company says the introduction of a non-invasive early detection test for CRC—such as ColoAlert—could significantly contribute to improving participation rates, supporting national health goals, and addressing a critical gap in prevention efforts.
“We are pleased to receive regulatory approval in Switzerland,” Guido Baechler, CEO of Mainz, said in a statement. “This supports our broader strategy to expand access to reliable CRC screening solutions for early detection for this devastating disease and ultimately to decrease related mortality rates.”
